Does health insurance cover immunotherapy in India — and where claims actually fail

Yes. India’s insurance regulator, IRDAI, lists “Immunotherapy — Monoclonal Antibody to be given as injection” among the modern treatment methods that every indemnity health policy must include. So a flat “immunotherapy is not covered” is usually wrong. What varies between policies is how much of the bill your insurer will actually release.

That distinction is the whole of this page. Covered is a yes-or-no question about the policy. Paid is a rupee figure, and it is set by four or five clauses buried in documents most families first open on the day of the first cycle. Cost decides whether treatment starts at all, so the honest thing is to read those clauses before you need them, not after a claim is short-settled.

Three documents hold the answers. The Customer Information Sheet is the plain-language summary IRDAI requires your insurer to give you, covering exclusions, sub-limits, deductibles and waiting periods. The policy schedule carries the numbers specific to your plan year. The policy wording carries the definitions — and definitions, not intentions, decide claims. Ask your insurer or agent for all three in writing if you do not have them.

Group and corporate policies carry the same IRDAI mandate, though caps and co-payments are often set by the employer’s scheme rather than by the insurer’s retail plan. Government health schemes work on a completely different basis and are covered further down this page.

The clause that matters most is the modern-treatment sub-limit. It caps what the insurer pays towards immunotherapy, written either as a share of the sum insured or as a fixed rupee ceiling. Four more limits sit around it: co-payment, room-rent linkage, waiting periods, and the annual sum insured itself.

All amounts and caps above are indicative only, as of August 2026, and differ by insurer, plan and policy year. The figure that governs your claim is the one printed in your own policy schedule. Nothing here is an assurance that a particular claim will be admitted.

Most denials come from policy wording, not from the medicine. The single commonest cause is classification: an infusion that finishes in a few hours gets recorded as OPD rather than day care, and the OPD exclusion then applies. The rest are documentation and timing.

• Recorded as OPD, not day care — the infusion is short, so it is billed as outpatient and refused under the OPD exclusion.
• Sub-limit reached — the insurer pays up to the modern-treatment cap and stops; families often read the balance as a rejection.
• Called experimental or investigational — frequently incorrect where the molecule holds a CDSCO-approved indication for that cancer.
• Indication mismatch — the drug is approved, but not for this cancer type, stage or line of therapy as prescribed.
• Waiting period not served — the initial 30-day or pre-existing-disease period had not elapsed when treatment began.
• Non-disclosure on the proposal form — a diagnosis that existed before the policy and was not declared.
• Pre-authorisation missing or incomplete — no prior approval on file, or prescription, reports and bills that do not agree with each other.

Each of these has a different remedy, and several are reversible on appeal. We have set them out one by one, with what to send and to whom, in why immunotherapy insurance claims get rejected.

1. 1

   Get all three documents

   Customer Information Sheet, policy schedule and full policy wording. Ask the insurer directly if your agent does not have them.

2. 2

   Find the modern-treatment clause

   Write down the exact cap in rupees. If it is expressed as a share of the sum insured, convert it to a number so the family is planning against something real.

3. 3

   Read the day-care and OPD definitions together

   Check whether the day-care annexure names chemotherapy or infusion therapy, and whether a separate clause excludes anything usually done in OPD. This pair decides admissibility.

4. 4

   Confirm your waiting-period position

   Note the policy start date, the date of diagnosis, and what was declared on the proposal form. If the diagnosis pre-dates the policy, expect the pre-existing-disease clause to be applied.

5. 5

   Ask for written pre-authorisation

   Have the hospital insurance desk file it naming the molecule, the planned number of cycles and the day-care setting. A written approval settles the classification argument in advance.

6. 6

   Get an itemised written estimate

   Drug, administration, day-care charges and monitoring listed separately, not one package figure. Estimates are indicative, as of August 2026, and should be re-confirmed at each cycle.

Scheme package rates and programme criteria change. Everything above is indicative, as of August 2026, and must be confirmed with the scheme office, insurer or programme before you plan around it.

Immunotherapy is administered as day care at CION centres, so the day-care wording in your policy is the clause we check first. The insurance desk files pre-authorisation naming the molecule, the cycle plan and the setting, and you get an itemised written estimate before anything begins.

Every case goes to a tumour board rather than resting on one doctor’s opinion, and the consultation runs 45 minutes because the money conversation is part of the medical conversation, not an afterthought. Where a course is not likely to be affordable in full, we say so at the start and discuss what is realistic, including the option of a different treatment plan.

Response-assessment scans are part of the cost picture too. PET-CT is coordinated at partner imaging centres rather than owned by CION, and imaging is billed and claimed separately from the drug, often against a different clause in the same policy. Ask for that to be estimated alongside the drug so the total is not a surprise at the second cycle.

What we cannot do is tell you a claim will be approved. That decision belongs to the insurer, on your policy wording. What we can do is make sure the classification, the prescription and the documentation give the claim its best possible footing.

• Why Immunotherapy Insurance Claims Get Rejected — each denial reason above, with the appeal route and the documents to send.
• Is Immunotherapy Covered Under Aarogyasri? — how the scheme’s package rates treat high-cost cancer drugs in Telangana and Andhra Pradesh.
• Ayushman Bharat (PM-JAY) and Immunotherapy — eligibility, empanelled hospitals, and where PM-JAY stops for immunotherapy.
• Immunotherapy at CION Cancer Clinics — what the treatment is, who it suits, and how day-care administration is organised.

This page is general information about insurance mechanics and does not replace a consultation or financial advice. Coverage, sub-limits and scheme rates differ by policy and change over time; all references here are indicative, as of August 2026. Always confirm your own position with your insurer, scheme office and treating oncology team.

Every estimate in writing, before you commit

No rushed decisions and no unnecessary tests. You see the itemised numbers, the insurance position and the alternatives together, then decide in your own time.